Tauklarify (florquinitau f-18)

Where it stands

According to the official records, the FDA approved Tauklarify (florquinitau f-18) on 2026-08-13. The sponsor is listed as Cerveau Lantheus, the application number is NDA220496, and the dosage form is a solution. The record describes it as a new medicine.

The records leave the therapeutic area and the approved indication blank. This analysis therefore cannot say what the product is approved to do, in which patients, or how it is used. The "f-18" in the name points to a fluorine-18 radiolabel, but the records do not state the product's class or use, and the label should be checked before drawing conclusions.

The only milestone on file is the approval itself. No earlier events, such as filing acceptance, advisory committee meetings or review extensions, are recorded.

Regulatory pathway and designations

The record lists one designation: new molecular entity (NME). In the US this means the active moiety had not previously been approved by the FDA. NMEs are reviewed under a full new drug application, and NDA220496 is the application number on file.

The records do not mention priority review, fast track, breakthrough therapy, orphan status or any other expedited-program designation. They also give no filing date or PDUFA goal date, so review duration cannot be assessed. The absence of these entries in the records does not show that none applied.

The CHMP opinion date is blank because the record covers a US approval. It says nothing about the product's status with the European Medicines Agency or any other authority.

Safety and pharmacovigilance

The records contain no safety information. They list no boxed warning, contraindications, adverse reaction data, risk management requirements or postmarketing commitments, so no safety conclusions can be drawn here.

For any newly approved NME, the standard sources are the FDA-approved prescribing information, the review documents on Drugs@FDA, and any postmarketing requirements or commitments. After launch, routine pharmacovigilance applies, including adverse event reporting and periodic safety reporting by the sponsor. Whether additional measures apply to this product is not stated in the records.

What to watch

The first step is to obtain the approved label to confirm the indication, the patient population, the dosing and administration details, and any warnings. Those details are missing from the records and are needed for any clinical, medical or commercial assessment.

Next, check the FDA review package for the basis of approval and for any postmarketing requirements. Also watch for announcements from Cerveau Lantheus on launch timing and on any plans to file outside the US. The records contain no information on any of these.